156 related articles for article (PubMed ID: 38238427)
21. Review of the registration of clinical trials in UMIN-CTR from 2 June 2005 to 1 June 2010 - focus on Japan domestic, academic clinical trials.
Tang W; Fukuzawa M; Ishikawa H; Tsutani K; Kiuchi T
Trials; 2013 Oct; 14():333. PubMed ID: 24124926
[TBL] [Abstract][Full Text] [Related]
22. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
Divoux J; Florent R; Jacobs M; Lequesne J; Grellard JM; San C; Grossi S; Kerdja K; Clarisse B; Boudier G; Cherifi F; Briand M; Dolivet E; Johnson A; Dubois B; Harter V; Lacroix J; Raboutet C; Marie B; Rousseau N; Blanc-Fournier C; Vaur D; Figeac M; Poulain L; Weiswald LB; Emile G
BMC Cancer; 2023 Sep; 23(1):883. PubMed ID: 37726786
[TBL] [Abstract][Full Text] [Related]
23. Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers.
Toney NJ; Opdenaker LM; Cicek K; Frerichs L; Kennington CR; Oberly S; Archinal H; Somasundaram R; Sims-Mourtada J
J Transl Med; 2022 Mar; 20(1):112. PubMed ID: 35255925
[TBL] [Abstract][Full Text] [Related]
24. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
25. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
26. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
27. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Graham R; Gazinska P; Zhang B; Khiabany A; Sinha S; Alaguthurai T; Flores-Borja F; Vicencio J; Beuron F; Roxanis I; Matkowski R; Liam-Or R; Tutt A; Ng T; Al-Jamal KT; Zhou Y; Irshad S
Front Immunol; 2023; 14():1204224. PubMed ID: 37441083
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
29. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
30. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Zhang J; Wang L; Xu X; Li X; Guan W; Meng T; Xu G
Front Oncol; 2020; 10():1787. PubMed ID: 33042828
[No Abstract] [Full Text] [Related]
32. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.
Obr AE; Kumar S; Chang YJ; Bulatowicz JJ; Barnes BJ; Birge RB; Lazzarino DA; Gallagher E; LeRoith D; Wood TL
Breast Cancer Res; 2018 Nov; 20(1):138. PubMed ID: 30458886
[TBL] [Abstract][Full Text] [Related]
33. Activation of Inflammatory Responses Correlate With Hedgehog Activation and Precede Expansion of Cancer Stem-Like Cells in an Animal Model of Residual Triple Negative Breast Cancer after Neoadjuvant Chemotherapy.
Arnold KM; Flynn NJ; Sims-Mourtada J
Cancer Stud Mol Med; 2015; 2(2):80-86. PubMed ID: 28203638
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Intratumoral Interrelation among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer.
Goda N; Nakashima C; Nagamine I; Otagaki S
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565267
[TBL] [Abstract][Full Text] [Related]
35. Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells.
Pindiprolu SKSS; Avasarala H; Dinakaran SK
Med Hypotheses; 2021 Dec; 157():110716. PubMed ID: 34731681
[TBL] [Abstract][Full Text] [Related]
36. Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer.
Ding R; Wang Y; Fan J; Tian Z; Wang S; Qin X; Su W; Wang Y
Front Oncol; 2023; 13():1108472. PubMed ID: 37377907
[TBL] [Abstract][Full Text] [Related]
37. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Jung HH; Kim JY; Cho EY; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958571
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
